Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Phase 4 Recruiting 100 enrolled Melbourne Health Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.

Timeline

Start: 2019-08-01
Primary completion: 2025-12-30
Completion: 2025-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Posaconazole	Small molecule	300 mg	Oral

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Summary

Timeline

Drugs

Indications